Chugai Pharmaceutical (OTCMKTS:CHGCY) Rating Increased to Hold at Nomura

Nomura upgraded shares of Chugai Pharmaceutical (OTCMKTS:CHGCY) to a hold rating in a research note issued to investors on Tuesday,Zacks reports.

Several other brokerages have also recently issued reports on CHGCY. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Finally, UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Chugai Pharmaceutical currently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Up 0.4%

Shares of Chugai Pharmaceutical stock opened at $21.57 on Tuesday. The company has a 50-day moving average of $22.16 and a two-hundred day moving average of $25.24. Chugai Pharmaceutical has a 12-month low of $20.43 and a 12-month high of $34.84. The stock has a market cap of $71.00 billion, a PE ratio of 23.45 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. The business had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. On average, sell-side analysts forecast that Chugai Pharmaceutical will post 0.96 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.